Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16020764 | 1.00 | CTSK (0.46) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL13103136 | 0.89 | PSMB5 (0.48) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL354119 | 0.84 | CAPN1 (0.43) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL8614263 | 0.81 | PSMB5 (0.46) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL8614260 | 0.81 | PSMB5 (0.46) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL18662379 | 0.80 | CA1 (0.42) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL18662377 | 0.80 | CA1 (0.42) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL8034346 | 0.79 | CTSK (0.49) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL9556266 | 0.79 | CTSK (0.52) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL7435374 | 0.79 | CTSK (0.52) | CTSKCTSLCTSBCTSSCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836161-B1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LTD PARTNERSHIP (CA) | 2016-07-20 | — | — | EP | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CTSK 347/4885CTSL 649/4885CTSB 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.